With Ph3 da­ta, Pfiz­er wants to have the ‘first and on­ly’ RSV vac­cine to cov­er adults as young as 18 years old

The race for RSV vac­cine mar­ket dom­i­nance con­tin­ues with Pfiz­er re­port­ing on Tues­day that Abrys­vo passed its reg­is­tra­tional test in at-risk peo­ple aged 18 to 59 years.

Al­though GSK has al­ready sub­mit­ted its bid for Arexvy’s la­bel ex­pan­sion in adults aged 50 to 59 years, a reg­u­la­to­ry win for Pfiz­er in adults as young as 18 years would make Abrys­vo the “first and on­ly” vac­cine to do so in this pop­u­la­tion. Both vac­cines are al­ready FDA-ap­proved in old­er adults aged 60 years and up, with GSK dom­i­nat­ing the mar­ket so far.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER